Thursday, October 26, 2017 11:58:54 AM
1st patient enrollment, mid trial data, enrollment completion and any other company events, conferences etc until establishment of a new price trend. Otherwise, IDRA to the back burner and wait.
What are the odds trial will be successful and meet all endpoints is a big part of choosing a strategy as well. Maybe the greed of the tutes helps answer that question. hmmm
Appreciate your thoughts.
IDRA
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM